{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:25:39Z","timestamp":1792081539425,"version":"4.4.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T00:00:00Z","timestamp":1618617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T00:00:00Z","timestamp":1618617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012921","name":"Royal College of Surgeons in Ireland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012921","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:italic>Summary<\/jats:italic>\n                    <\/jats:title>\n                    <jats:p>Gaps in pharmacological treatment for osteoporosis can reduce effectiveness. Among older adults, we found about half of new users of oral bisphosphonate and denosumab persisted with their treatment at 2 years, with few switching to alternative therapy. Persistence is suboptimal and warrants evaluation of interventions to improve this.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Gaps in pharmacological treatment for osteoporosis can reduce effectiveness. This study aimed to estimate persistence rates for oral bisphosphonates and denosumab in older primary care patients and identify factors associated with discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Older patients newly prescribed oral bisphosphonates or denosumab during 2012\u20132017 were identified from 44 general practices (GP) in Ireland. Persistence without a coverage gap of &gt;90 days was calculated for both medications from therapy initiation. Factors associated with time to discontinuation were explored using Cox regression analysis. Exposures included age group, osteoporosis diagnosis, fracture history, calcium\/vitamin D prescription, number of other medications, health cover, dosing frequency (bisphosphonates) and previous bone-health medication (denosumab).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 41,901 patients,\n                      <jats:italic>n<\/jats:italic>\n                      =1569 were newly initiated on oral bisphosphonates and\n                      <jats:italic>n<\/jats:italic>\n                      =1615 on denosumab. Two-year persistence was 49.4% for oral bisphosphonates and 53.8% for denosumab and &lt;10% were switched to other medication. Having state-funded health cover was associated with a lower hazard of discontinuation for both oral bisphosphonates (HR=0.49, 95% CI=0.36\u20130.66,\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.01) and denosumab (HR=0.71, 95% CI=0.57\u20130.89,\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.01). Older age group, number of medications and calcium\/vitamin D prescription were also associated with better bisphosphonate persistence, while having osteoporosis diagnosed was associated with better denosumab persistence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Persistence for osteoporosis medications is suboptimal. Of concern, few patients are switched to other bone-health treatments when denosumab is stopped which could increase fracture risk. Free access to GP services and medications may have resulted in better medication persistence in this cohort. Future research should explore prescribing choices in primary care osteoporosis management and evaluate cost-effectiveness of interventions for improving persistence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11657-021-00932-7","type":"journal-article","created":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T08:02:54Z","timestamp":1618646574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Persistence with oral bisphosphonates and denosumab among older adults in primary care in Ireland"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8920-7419","authenticated-orcid":false,"given":"Mary E.","family":"Walsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5896-5783","authenticated-orcid":false,"given":"Tom","family":"Fahey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9838-3625","authenticated-orcid":false,"given":"Frank","family":"Moriarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,17]]},"reference":[{"key":"932_CR1","doi-asserted-by":"publisher","first-page":"166","DOI":"10.5312\/wjo.v10.i3.166","volume":"10","author":"C Downey","year":"2019","unstructured":"Downey C, Kelly M, Quinlan JF (2019) Changing trends in the mortality rate at 1-year post hip fracture - a systematic review. World J Orthop 10:166\u2013175. https:\/\/doi.org\/10.5312\/wjo.v10.i3.166","journal-title":"World J Orthop"},{"key":"932_CR2","unstructured":"Kanis JA, on behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at the primary health-care level. In: World Health Organization Collaborating Centre for Metabolic Bone Diseases (ed) University of Sheffield, UK"},{"key":"932_CR3","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1002\/jbmr.2269","volume":"29","author":"NC Wright","year":"2014","unstructured":"Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, Dawson-Hughes B (2014) The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res 29:2520\u20132526. https:\/\/doi.org\/10.1002\/jbmr.2269","journal-title":"J Bone Miner Res"},{"key":"932_CR4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/jbmr.2072","volume":"29","author":"S Amin","year":"2014","unstructured":"Amin S, Achenbach SJ, Atkinson EJ, Khosla S, Melton LJ 3rd (2014) Trends in fracture incidence: a population-based study over 20 years. J Bone Miner Res 29:581\u2013589. https:\/\/doi.org\/10.1002\/jbmr.2072","journal-title":"J Bone Miner Res"},{"key":"932_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11657-017-0324-5","volume":"12","author":"J Compston","year":"2017","unstructured":"Compston J, Cooper A, Cooper C et al (2017) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 12:43. https:\/\/doi.org\/10.1007\/s11657-017-0324-5","journal-title":"Arch Osteoporos"},{"key":"932_CR6","unstructured":"Scottish Intercollegiate Guideline Network (2015) Management of osteoporosis and the prevention of fragility fractures (SIGN Guideline No. 142). Edinburgh"},{"key":"932_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta24290","volume":"24","author":"S Davis","year":"2020","unstructured":"Davis S, Simpson E, Hamilton J, James MM, Rawdin A, Wong R, Goka E, Gittoes N, Selby P (2020) Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation. Health Technol Assess 24:1\u2013314. https:\/\/doi.org\/10.3310\/hta24290","journal-title":"Health Technol Assess"},{"key":"932_CR8","unstructured":"National Institute for Health and Care Excellence (2014) Osteoarthritis: care and management. NICE guideline (CG177)"},{"key":"932_CR9","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/jgs.14668","volume":"65","author":"S Nayak","year":"2017","unstructured":"Nayak S, Greenspan SL (2017) Osteoporosis treatment efficacy for men: a systematic review and meta-analysis. J Am Geriatr Soc 65:490\u2013495. https:\/\/doi.org\/10.1111\/jgs.14668","journal-title":"J Am Geriatr Soc"},{"key":"932_CR10","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1210\/jc.2014-4079","volume":"100","author":"BL Langdahl","year":"2015","unstructured":"Langdahl BL, Teglbj\u00e6rg CS, Ho PR, Chapurlat R, Czerwinski E, Kendler DL, Reginster JY, Kivitz A, Lewiecki EM, Miller PD, Bolognese MA, McClung MR, Bone HG, Ljunggren \u00d6, Abrahamsen B, Gruntmanis U, Yang YC, Wagman RB, Mirza F, Siddhanti S, Orwoll E (2015) A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. J Clin Endocrinol Metab 100:1335\u20131342. https:\/\/doi.org\/10.1210\/jc.2014-4079","journal-title":"J Clin Endocrinol Metab"},{"key":"932_CR11","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jval.2012.02.001","volume":"15","author":"M Hiligsmann","year":"2012","unstructured":"Hiligsmann M, McGowan B, Bennett K, Barry M, Reginster JY (2012) The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health 15:604\u2013612. https:\/\/doi.org\/10.1016\/j.jval.2012.02.001","journal-title":"Value Health"},{"key":"932_CR12","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jval.2010.11.010","volume":"14","author":"S Ross","year":"2011","unstructured":"Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E (2011) A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health 14:571\u2013581. https:\/\/doi.org\/10.1016\/j.jval.2010.11.010","journal-title":"Value Health"},{"key":"932_CR13","doi-asserted-by":"publisher","first-page":"e027049","DOI":"10.1136\/bmjopen-2018-027049","volume":"9","author":"F Fatoye","year":"2019","unstructured":"Fatoye F, Smith P, Gebrye T, Yeowell G (2019) Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open 9:e027049. https:\/\/doi.org\/10.1136\/bmjopen-2018-027049","journal-title":"BMJ Open"},{"key":"932_CR14","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1007\/s00198-020-05507-9","volume":"31","author":"G Koller","year":"2020","unstructured":"Koller G, Goetz V, Vandermeer B, Homik J, McAlister FA, Kendler D, Ye C (2020) Persistence and adherence to parenteral osteoporosis therapies: a systematic review. Osteoporos Int 31:2093\u20132102. https:\/\/doi.org\/10.1007\/s00198-020-05507-9","journal-title":"Osteoporos Int"},{"key":"932_CR15","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019) Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab 104:1595\u20131622. https:\/\/doi.org\/10.1210\/jc.2019-00221","journal-title":"J Clin Endocrinol Metab"},{"key":"932_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/ep161435.Gl","volume":"22","author":"PM Camacho","year":"2016","unstructured":"Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, Miller PD, Narula HS, Pessah-Pollack R, Tangpricha V, Wimalawansa SJ, Watts NB (2016) American association of clinical endocrinologists and American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2016. Endocr Pract 22:1\u201342. https:\/\/doi.org\/10.4158\/ep161435.Gl","journal-title":"Endocr Pract"},{"key":"932_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.maturitas.2017.04.008","volume":"101","author":"P Anagnostis","year":"2017","unstructured":"Anagnostis P, Paschou SA, Mintziori G, Ceausu I, Depypere H, Lambrinoudaki I, Mueck A, P\u00e9rez-L\u00f3pez FR, Rees M, Senturk LM, Simoncini T, Stevenson JC, Stute P, Tr\u00e9mollieres FA, Goulis DG (2017) Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas. 101:23\u201330. https:\/\/doi.org\/10.1016\/j.maturitas.2017.04.008","journal-title":"Maturitas."},{"key":"932_CR18","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1210\/clinem\/dgz321","volume":"105","author":"H Lyu","year":"2020","unstructured":"Lyu H, Zhao SS, Yoshida K, Tedeschi SK, Xu C, Nigwekar SU, Leder BZ, Solomon DH (2020) Delayed denosumab injections and bone mineral density response: an electronic health record-based study. J Clin Endocrinol Metab 105:1435\u20131444. https:\/\/doi.org\/10.1210\/clinem\/dgz321","journal-title":"J Clin Endocrinol Metab"},{"key":"932_CR19","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972\u2013980. https:\/\/doi.org\/10.1210\/jc.2010-1502","journal-title":"J Clin Endocrinol Metab"},{"key":"932_CR20","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JEB, McClung M, Roux C, T\u00f6rring O, Valter I, Wang AT, Brown JP (2018) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res 33:190\u2013198. https:\/\/doi.org\/10.1002\/jbmr.3337","journal-title":"J Bone Miner Res"},{"key":"932_CR21","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/jbmr.4098","volume":"35","author":"AS S\u00f8lling","year":"2020","unstructured":"S\u00f8lling AS, Harsl\u00f8f T, Langdahl B (2020) Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial. J Bone Miner Res 35:1858\u20131870. https:\/\/doi.org\/10.1002\/jbmr.4098","journal-title":"J Bone Miner Res"},{"key":"932_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Gua\u00f1abens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone. 105:11\u201317. https:\/\/doi.org\/10.1016\/j.bone.2017.08.003","journal-title":"Bone."},{"key":"932_CR23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12875-020-01103-2","volume":"21","author":"P Naik-Panvelkar","year":"2020","unstructured":"Naik-Panvelkar P, Norman S, Elgebaly Z, Elliott J, Pollack A, Thistlethwaite J, Weston C, Seibel MJ (2020) Osteoporosis management in Australian general practice: an analysis of current osteoporosis treatment patterns and gaps in practice. BMC Fam Pract 21:32. https:\/\/doi.org\/10.1186\/s12875-020-01103-2","journal-title":"BMC Fam Pract"},{"key":"932_CR24","doi-asserted-by":"publisher","first-page":"e1001885","DOI":"10.1371\/journal.pmed.1001885","volume":"12","author":"EI Benchimol","year":"2015","unstructured":"Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sorensen HT, von Elm E, Langan SM (2015) The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med 12:e1001885. https:\/\/doi.org\/10.1371\/journal.pmed.1001885","journal-title":"PLoS Med"},{"key":"932_CR25","doi-asserted-by":"publisher","first-page":"e024747","DOI":"10.1136\/bmjopen-2018-024747","volume":"9","author":"P Redmond","year":"2019","unstructured":"Redmond P, McDowell R, Grimes TC, Boland F, McDonnell R, Hughes C, Fahey T (2019) Unintended discontinuation of medication following hospitalisation: a retrospective cohort study. BMJ Open 9:e024747. https:\/\/doi.org\/10.1136\/bmjopen-2018-024747","journal-title":"BMJ Open"},{"key":"932_CR26","doi-asserted-by":"publisher","unstructured":"Walsh ME, Nerdrum M, Fahey T, Moriarty F (2021) Factors associated with initiation of bone-health medication among older adults in primary care in Ireland. Age and Ageing 1\u20138. https:\/\/doi.org\/10.1093\/ageing\/afab033.","DOI":"10.1093\/ageing\/afab033"},{"key":"932_CR27","unstructured":"Health Service Executive (2019) Medical Card and GP Visit Card National Assessment Guidelines. Version 3"},{"key":"932_CR28","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s11845-013-0935-9","volume":"182","author":"B McGowan","year":"2013","unstructured":"McGowan B, Bennett K, Casey MC, Doherty J, Silke C, Whelan B (2013) Comparison of prescribing and adherence patterns of anti-osteoporotic medications post-admission for fragility type fracture in an urban teaching hospital and a rural teaching hospital in Ireland between 2005 and 2008. Ir J Med Sci 182:601\u2013608. https:\/\/doi.org\/10.1007\/s11845-013-0935-9","journal-title":"Ir J Med Sci"},{"key":"932_CR29","doi-asserted-by":"publisher","first-page":"841","DOI":"10.4158\/ep161678.ra","volume":"23","author":"SG Albert","year":"2017","unstructured":"Albert SG, Reddy S (2017) Clinical evaluation of cost efficacy of drugs for treatment of osteoporosis: a meta-analysis. Endocr Pract 23:841\u2013856. https:\/\/doi.org\/10.4158\/ep161678.ra","journal-title":"Endocr Pract"},{"key":"932_CR30","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s00198-014-2941-9","volume":"26","author":"ES LeBlanc","year":"2015","unstructured":"LeBlanc ES, Rosales AG, Balasubramanian A, O'Malley CD, Egbuna O, Friess D, Perrin NA (2015) Risk factors for fracture among current, persistent users of bisphosphonates. Osteoporos Int 26:713\u2013725. https:\/\/doi.org\/10.1007\/s00198-014-2941-9","journal-title":"Osteoporos Int"},{"key":"932_CR31","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00198-011-1549-6","volume":"23","author":"E Landfeldt","year":"2012","unstructured":"Landfeldt E, Str\u00f6m O, Robbins S, Borgstr\u00f6m F (2012) Adherence to treatment of primary osteoporosis and its association to fractures--the Swedish Adherence Register Analysis (SARA). Osteoporos Int 23:433\u2013443. https:\/\/doi.org\/10.1007\/s00198-011-1549-6","journal-title":"Osteoporos Int"},{"key":"932_CR32","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00223-015-0082-6","volume":"98","author":"P Lakatos","year":"2016","unstructured":"Lakatos P, Tak\u00e1cs I, Marton I, T\u00f3th E, Zoltan C, Lang Z, Psachoulia E, Intorcia M (2016) A retrospective longitudinal database study of persistence and compliance with treatment of osteoporosis in Hungary. Calcif Tissue Int 98:215\u2013225. https:\/\/doi.org\/10.1007\/s00223-015-0082-6","journal-title":"Calcif Tissue Int"},{"key":"932_CR33","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1007\/s00198-006-0136-8","volume":"17","author":"JR Curtis","year":"2006","unstructured":"Curtis JR, Westfall AO, Allison JJ, Freeman A, Saag KG (2006) Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users. Osteoporos Int 17:1268\u20131274. https:\/\/doi.org\/10.1007\/s00198-006-0136-8","journal-title":"Osteoporos Int"},{"key":"932_CR34","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00198-011-1645-7","volume":"23","author":"AM Burden","year":"2012","unstructured":"Burden AM, Paterson JM, Solomon DH, Mamdani M, Juurlink DN, Cadarette SM (2012) Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada. Osteoporos Int 23:1075\u20131082. https:\/\/doi.org\/10.1007\/s00198-011-1645-7","journal-title":"Osteoporos Int"},{"key":"932_CR35","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s00198-019-05104-5","volume":"30","author":"M Hiligsmann","year":"2019","unstructured":"Hiligsmann M, Cornelissen D, Vrijens B, Abrahamsen B, al-Daghri N, Biver E, Brandi ML, Bruy\u00e8re O, Burlet N, Cooper C, Cortet B, Dennison E, Diez-Perez A, Gasparik A, Grosso A, Hadji P, Halbout P, Kanis JA, Kaufman JM, Laslop A, Maggi S, Rizzoli R, Thomas T, Tuzun S, Vlaskovska M, Reginster JY (2019) Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF). Osteoporos Int 30:2155\u20132165. https:\/\/doi.org\/10.1007\/s00198-019-05104-5","journal-title":"Osteoporos Int"},{"key":"932_CR36","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00198-009-0930-1","volume":"21","author":"FE Cott\u00e9","year":"2010","unstructured":"Cott\u00e9 FE, Fardellone P, Mercier F, Gaudin AF, Roux C (2010) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 21:145\u2013155. https:\/\/doi.org\/10.1007\/s00198-009-0930-1","journal-title":"Osteoporos Int"},{"key":"932_CR37","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11657-017-0351-2","volume":"12","author":"A Fahrleitner-Pammer","year":"2017","unstructured":"Fahrleitner-Pammer A, Papaioannou N, Gielen E, Feudjo Tepie M, Toffis C, Frieling I, Geusens P, Makras P, Boschitsch E, Callens J, Anastasilakis AD, Niedhart C, Resch H, Kalouche-Khalil L, Hadji P (2017) Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium. Arch Osteoporos 12:58. https:\/\/doi.org\/10.1007\/s11657-017-0351-2","journal-title":"Arch Osteoporos"},{"key":"932_CR38","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/fampra\/cmw120","volume":"34","author":"BC van der Zwaard","year":"2017","unstructured":"van der Zwaard BC, van Hout W, Hugtenburg JG, van der Horst HE, Elders PJM (2017) Adherence and persistence of patients using oral bone sparing drugs in primary care. Fam Pract 34:525\u2013531. https:\/\/doi.org\/10.1093\/fampra\/cmw120","journal-title":"Fam Pract"},{"key":"932_CR39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11657-017-0331-6","volume":"12","author":"E Mart\u00edn-Merino","year":"2017","unstructured":"Mart\u00edn-Merino E, Huerta-\u00c1lvarez C, Prieto-Alhambra D, Montero-Corominas D (2017) Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis. Arch Osteoporos 12:39. https:\/\/doi.org\/10.1007\/s11657-017-0331-6","journal-title":"Arch Osteoporos"},{"key":"932_CR40","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00198-013-2610-4","volume":"25","author":"K Ganda","year":"2014","unstructured":"Ganda K, Schaffer A, Pearson S, Seibel MJ (2014) Compliance and persistence to oral bisphosphonate therapy following initiation within a secondary fracture prevention program: a randomised controlled trial of specialist vs. non-specialist management. Osteoporos Int 25:1345\u20131355. https:\/\/doi.org\/10.1007\/s00198-013-2610-4","journal-title":"Osteoporos Int"},{"key":"932_CR41","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00198-018-4702-7","volume":"30","author":"FA McAlister","year":"2019","unstructured":"McAlister FA, Ye C, Beaupre LA, Rowe BH, Johnson JA, Bellerose D, Hassan I, Majumdar SR (2019) Adherence to osteoporosis therapy after an upper extremity fracture: a pre-specified substudy of the C-STOP randomized controlled trial. Osteoporos Int 30:127\u2013134. https:\/\/doi.org\/10.1007\/s00198-018-4702-7","journal-title":"Osteoporos Int"},{"key":"932_CR42","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00198-019-05228-8","volume":"31","author":"J Morley","year":"2020","unstructured":"Morley J, Moayyeri A, Ali L, Taylor A, Feudjo-Tepie M, Hamilton L, Bayly J (2020) Persistence and compliance with osteoporosis therapies among postmenopausal women in the UK Clinical Practice Research Datalink. Osteoporos Int 31:533\u2013545. https:\/\/doi.org\/10.1007\/s00198-019-05228-8","journal-title":"Osteoporos Int"},{"key":"932_CR43","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s00198-020-05378-0","volume":"31","author":"D Cornelissen","year":"2020","unstructured":"Cornelissen D, de Kunder S, Si L, Reginster JY, Evers S, Boonen A, Hiligsmann M (2020) Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review. Osteoporos Int 31:1645\u20131669. https:\/\/doi.org\/10.1007\/s00198-020-05378-0","journal-title":"Osteoporos Int"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-021-00932-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-021-00932-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-021-00932-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T10:45:52Z","timestamp":1642070752000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-021-00932-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,17]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["932"],"URL":"https:\/\/doi.org\/10.1007\/s11657-021-00932-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.10.05.20207290","asserted-by":"object"}]},"ISSN":["1862-3522","1862-3514"],"issn-type":[{"value":"1862-3522","type":"print"},{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,17]]},"assertion":[{"value":"14 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Irish College of General Practitioners.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This study involved the analysis of anonymous routinely collected data. No individual patient consent was obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"71"}}